Evidence map›Paper›PMID 21220529›Full record

ArticleAntimicrobial agents and chemotherapy2011

Panton-valentine leukocidin-positive and toxic shock syndrome toxin 1-positive methicillin-resistant Staphylococcus aureus: a French multicenter prospective study in 2008.

Jérôme Robert, Anne Tristan, Laurent Cavalié, Jean-Winoc Decousser, Michèle Bes, Jerome Etienne, Frédéric Laurent, ONERBA (Observatoire National de l'Epidémiologie de Résistance Bactérienne aux Antibiotiques)

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Methicillin-ResistantToxins · 2020
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. The incidence of Staphylococcus aureus ST8-USA300 among French pediatric inpatients is rising.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015
    Article
  11. Article
  12. Article
  13. Review
  14. Community-acquired methicillin-resistant Staphylococcus aureus clones circulating in Belgium from 2005 to 2009: changing epidemiology.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013
    Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jérôme RobertBactériologie-Hygiène, UFR de Médecine Pierre et Marie Curie, Site Pitié-Salpêtrière, 91 Bd de l'hôpital, 75634 Paris Cedex 13, France. jerome.robert@psl.aphp.fr.
Anne Tristan
Laurent Cavalié
Jean-Winoc Decousser
Michèle Bes
Jerome Etienne
Frédéric Laurent
ONERBA (Observatoire National de l'Epidémiologie de Résistance Bactérienne aux Antibiotiques)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidemiology of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) differs from country to country. We assess the features of the ST80 European clone, which is the most prevalent PVL-positive CA-MRSA clone in Europe, and the TSST-1 ST5 clone that was recently described in France. In 2008, all MRSA strains susceptible to fluoroquinolones and gentamicin and resistant to fusidic acid that were isolated in 104 French laboratories were characterized using agr alleles, spa typing, and the staphylococcal cassette chromosome mec element and PCR profiling of 21 toxin genes. Three phenotypes were defined: (i) kanamycin resistant, associated with the ST80 clone; (ii) kanamycin and tobramycin resistant, associated with the ST5 clone; and (iii) aminoglycoside susceptible, which was less frequently associated with the ST5 clone. Among the 7,253 MRSA strains isolated, 91 (1.3%) were ST80 CA-MRSA (89 phenotype 1) and 190 (2.6%) were ST5 CA-MRSA (146 phenotype 2, 42 phenotype 3). Compared to the latter, ST80 CA-MRSAs were more likely to be community acquired (80% versus 46%) and found in young patients (median age, 26.0 years versus 49.5 years) with deep cutaneous infections (48% versus 6%). They were less likely to be tetracycline susceptible (22% versus 85%) and to be isolated from respiratory infections (6% versus 27%). The TSST-1 ST5 clone has rapidly emerged in France and has become even more prevalent than the ST80 European clone, whose prevalence has remained stable. The epidemiological and clinical patterns of the two clones differ drastically. Given the low prevalence of both among all staphylococcal infections, no modification of antibiotic recommendations is required yet.

Indexed as

AdultAminoglycosidesAnti-Bacterial AgentsBacterial ToxinsCommunity-Acquired InfectionsEnterotoxinsExotoxinsFranceHumansKanamycinLeukocidinsMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMiddle AgedProspective StudiesRespiratory Tract InfectionsAminoglycosidesAnti-Bacterial AgentsBacterial Toxinsenterotoxin F, StaphylococcalEnterotoxinsExotoxinsKanamycinLeukocidinsPanton-Valentine leukocidinSuperantigensTetracyclineTobramycin

Identifiers

PMID21220529
PMCPMC3067161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.